A Prospective Study on the Real-World Use of Efgartigimod for Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy CIDP

What this Trial Is About

Researchers are studying the real-world effectiveness of efgartigimod in treating adults with chronic inflammatory demyelinating polyradiculoneuropathy CIDP. The study aims to understand how patients respond to the treatment over time, describe their treatment experiences, and assess their use of healthcare services. This observational study follows participants for up to two years after they begin efgartigimod treatment. Participants will receive efgartigimod according to the approved treatment guidelines in their country, with treatment decisions made by their doctors as part of usual care. Since this is a noninterventional study, no specific treatments are assigned by the researchers instead, the study observes how patients use efgartigimod in routine practice. Throughout the study, participants will be monitored for changes in their disability and quality of life using measures like the adjusted inflammatory neuropathy cause and treatment aINCAT score, I-RODS, grip strength, and EQ-5D values. These assessments will occur over a period of up to two years and three months, helping researchers understand the impact of efgartigimod on patients living with CIDP.

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study